Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
Dirk Sibbing, Dániel Aradi, Dimitrios K. Alexopoulos et al. · JACC: Cardiovascular Interventions · 2019
Cited by 537 works. doi:10.1016/j.jcin.2019.03.034 Open-access PDF
Authors
- Dirk Sibbing
- Dániel Aradi
- Dimitrios K. Alexopoulos
- Jurriën M. ten Berg
- Deepak L. Bhatt
- Laurent Bonello
- Jean‐Philippe Collet
- Thomas Cuisset
- Francesco Franchi
- Lisa Groß
- Paul Alfred Gurbel
- Young‐Hoon Jeong
- Roxana Mehran
- David J. Moliterno
- Franz‐Josef Neumann
- Naveen L. Pereira
- Matthew J. Price
- Marc Steven Sabatine
- Derek Y F So
- Gregg W. Stone
References
- Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- A Randomized Comparison of Antiplatelet and Anticoagulant Therapy after the Placement of Coronary-Artery Stents
- 2018 ESC/EACTS Guidelines on myocardial revascularization
- Clopidogrel for Coronary Stenting
- Cytochrome P-450 Polymorphisms and Response to Clopidogrel
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
- Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
- Double-Blind Study of the Safety of Clopidogrel With and Without a Loading Dose in Combination With Aspirin Compared With Ticlopidine in Combination With Aspirin After Coronary Stenting
- Genetic Determinants of Response to Clopidogrel and Cardiovascular Events